Ophthalmic drug delivery device

• US 20060039952A1
• Filed: 10/12/2005
• Published: 02/23/2006
• Est. Priority Date: 07/10/2003
• Status: Abandoned Application

• Current Assignee: Yoseph Yaacobi
• Original Assignee: Yoseph Yaacobi
• Inventors: Yaacobi, Yoseph
• Application Number:
  US11/248,727
• Publication Number:
  US 20060039952A1
• Time in Patent Office: Days
• US Class Current: 424/427
• CPC Class Codes: A61F 2250/0067 Means for introducing or releasing pharmaceutical products into the body
• CPC Class Codes: A61F 9/0017 implantable in, or in contact with, the eye, e.g. ocular inserts

Abstract

Ophthalmic drug delivery devices useful for delivery of pharmaceutically active agents to the posterior segment of the eye are disclosed. The devices may include extensions, immobilizing structures, and/or geometries to help properly locate, and prevent migration of, the devices.

Claims

1. A drug delivery device for an eye, said eye comprising a sclera, a macula, and an extraocular muscle, comprising:

a pharmaceutically active agent; and

a body having an extension for accomodating said extraocular muscle;

whereby when said device is disposed on an outer surface of said sclera so that said extension accomodates said extraocular muscle, said pharmaceutically active agent is disposed proximate said macula.

2. The drug delivery device of claim 1 whereby when said device is disposed on an outer surface of said sclera so that said extension accomodates said extraocular muscle, said pharmaceutically active agent is disposed above said macula.

3. The drug delivery device of claim 1 wherein said extraocular muscle is an inferior oblique muscle.

4. The drug delivery device of claim 1 wherein said extraocular muscle is a lateral rectus muscle.

5. The drug delivery device of claim 1 wherein said extraocular muscle is a superior rectus muscle.

6. A drug delivery device for an eye, said eye comprising a sclera and an extraocular muscle, comprising:

a pharmaceutically active agent; and

a body having an extension for accomodating said extraocular muscle;

whereby when said device is disposed on an outer surface of said sclera so that said extension accomodates said extraocular muscle, said extension helps to immobilize and to prevent migration of said device.

7. The drug delivery device of claim 6 wherein said extraocular muscle is an inferior oblique muscle.

8. The drug delivery device of claim 6 wherein said extraocular muscle is a lateral rectus muscle.

9. The drug delivery device of claim 6 wherein said extraocular muscle is a superior rectus muscle.

10. A drug delivery device for an eye, said eye comprising an extraocular muscle, comprising:

a pharmaceutically active agent; and

a body having an extension for accomodating said extraocular muscle, said extension being capable of extending from said body in a first position so as to accommodate said extraocular muscle, and said extension being capable of folding above or beneath said body in a second position so as to facilitate implantation of said device.

11. A drug delivery device for an eye, said eye comprising a sclera, comprising:

a pharmaceutically active agent; and

a body having a scleral surface for contacting said sclera and an immobilizing structure disposed on said scleral surface.

12. The drug delivery device of claim 11 wherein said immobilizing structure is a suction cup.

13. The drug delivery device of claim 11 wherein said immobilizing structure is a bioadhesive coating.

14. The drug delivery device of claim 11 wherein said immobilizing structure is a region containing a sharp prong.

15. A drug delivery device for an eye, said eye comprising a sclera, a macula, a superior rectus muscle, and a lateral rectus muscle, comprising:

a body having;

a scleral surface;

a well having an opening to said scleral surface; and

a geometry that facilitates an implantation of said device on an outer surface of said sclera, between said superior rectus muscle and said lateral rectus muscle, beneath said lateral rectus muscle, and with said well disposed proximate said macula; and

an inner core disposed in said well and comprising a pharmaceutically active agent.

16. The drug delivery device of claim 15 wherein said inner core is a tablet.

17. The drug delivery device of claim 15 wherein said eye comprises a Tenon'"'"'s capsule, and said geometry facilitates an implantation of said device beneath said Tenon'"'"'s capsule.

18. The drug delivery device of claim 15 wherein said geometry facilitates an implantation of said device with said well disposed above said macula.

19. The drug delivery device of claim 18 wherein said macula comprises a fovea, and said geometry facilitates an implantation of said device with said well disposed above said fovea.

20. The drug delivery device of claim 15 wherein said body comprises an orbital surface, and said geometry is a generally club-shaped geometry when viewed from said scleral surface or said orbital surface.

21. The drug delivery device of claim 15 wherein said body comprises an orbital surface, and said geometry is a generally arc-shaped geometry when viewed from said scleral surface or said orbital surface.

22. The drug delivery device of claim 15 wherein said scleral surface has a radius of curvature that facilitates contact with said sclera.

23. A method of delivering a pharmaceutically active agent to an eye, said eye comprising a sclera, a macula, a superior rectus muscle, and a lateral rectus muscle, comprising the steps of:

providing a drug delivery device comprising;

a pharmaceutically active agent; and

a body having a geometry that facilitates an implantation of said device on an outer surface of said sclera, between said superior rectus muscle and said lateral rectus muscle, beneath said lateral rectus muscle, and with said pharmaceutically active agent disposed proximate said macula; and

disposing said device on an outer surface of said sclera, between said superior rectus muscle and said lateral rectus muscle, beneath said lateral rectus muscle, and with said pharmaceutically active agent disposed proximate said macula.

24. The method of claim 23 wherein said eye comprises a Tenon'"'"'s capsule, and said disposing step comprises disposing said device below said Tenon'"'"'s capsule.

25. The method of claim 23 wherein said disposing step comprises disposing said pharmaceutically active agent above said macula.

26. The method of claim 25 wherein said disposing step comprises disposing said pharmaceutically active agent above said fovea.

27. The method of claim 23 wherein said body comprises a scleral surface and an orbital surface, and said geometry is a generally club-shaped geometry when viewed from said scleral surface or said orbital surface.

28. The method of claim 23 wherein said body comprises a scleral surface and an orbital surface, and said geometry is a generally arc-shaped geometry when viewed from said scleral surface or said orbital surface.

29. The method of claim 23 wherein said device comprises an inner core comprising said pharmaceutically active agent, and said body comprises a scleral surface and a well having an opening to said scleral surface for receiving said inner core.

30. The method of claim 29 wherein said inner core is a tablet.